• Agenus will present three-year overall survival data for botensilimab with balstilimab in recurrent ovarian cancer at IGCS 2026.
• The poster will cover outcomes from the Phase 1b C-800-01 study cohort, including platinum-refractory or platinum-resistant patients.
• Results will be analyzed by platinum sensitivity status, aiming to clarify durability of benefit in hard-to-treat disease.
• Presentation is scheduled for Oct. 3, 2026, at the IGCS Annual Global Meeting in Montreal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609100730BIZWIRE_USPR_____20260910_BW303866) on September 10, 2026, and is solely responsible for the information contained therein.